| LIQUIDIA CORP. DL-,001 |
| USA |
| Gesundheit |
| US53635D2027 / A2JRNS |
| LT4 (Frankfurt) / LQDA (NASDAQ) |
| FRA:LT4, ETR:LT4, LT4:GR, NASDAQ:LQDA |
| - |
| https://liquidia.com/ |
|
Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in p..
>Volltext.. |
| 6076.3 Mio. EUR |
| 5987.68 Mio. EUR |
| 391.04 Mio. EUR |
| 147.66 Mio. EUR |
| 120.2 Mio. EUR |
| 1.36 EUR |
| 158.61 Mio. EUR |
| 246.45 Mio. EUR |
| 145.44 Mio. EUR |
| 1.5 |
| 2307.06% |
| - |
| - |
| - |
| - |
| 10 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 28.219.853 Euro. |
| LIQUIDIA |
| 14.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|